Sökning: "CD40"
Visar resultat 1 - 5 av 89 avhandlingar innehållade ordet CD40.
1. The CD40 Receptor - Target,Tool and Technology
Sammanfattning : CD40 is a cell surface receptor of pivotal importance that is expressed on several of the cells in the immune system. It is critical for many important events, such as T cell dependent B cell activation, isotype switching, somatic mutation and generation of B cell memory. LÄS MER
2. Intratumoral CD40 stimulating therapy in patients with advanced cancer
Sammanfattning : CD40-CD40L interaction activates DCs to become highly efficient APCs and skews the adaptive immune response towards a Th I phenotype driving cytotoxic T cells, M1 macrophages and natural killer cells. Furthermore, engagement of CD40L to CD40 positive cancer cells can have direct anti-proliferative effects, induce apoptosis and increase expression of MHC and other co-stimulatory molecules, thereby enhancing cancer cell recognition. LÄS MER
3. Tissue Factor and CD40 Ligand : Markers for the Interplay of Coagulation and Inflammation in the Acute Coronary Syndrome
Sammanfattning : BACKGROUND: Tissue factor (TF) is a 47 kDa transmembrane glycoprotein known as the main initiator of blood coagulation. CD40 ligand is another membrane molecule, which ligates to cell types associated with atherosclerotic plaques thereby mediating intraplaque inflammation and weakening of the fibrous cap. LÄS MER
4. Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies
Sammanfattning : Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. LÄS MER
5. Diffuse large B-cell lymphoma - tumour characteristics on RNA and protein level associated with prognosis
Sammanfattning : Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma subtype. In Sweden 450 new cases are diagnosed annually. With modern anthracycline-containing chemotherapy DLBCL is potentially curable, with an estimated overall cure rate of approximately 50% for patients with advanced stage disease. LÄS MER